share_log

Senti Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Rajangam Kanya

SEC announcement ·  Feb 2 17:33
Summary by Moomoo AI
Senti Biosciences, Inc. (SNTI.US) reported that its Chief Medical & Development Officer, Rajangam Kanya, was granted 101,000 shares of common stock on February 1, 2024. The transaction, which was completed on the same day, was a grant with no cost associated with the acquisition. Following this transaction, Kanya directly holds a total of 101,000 shares in the company. The grant is part of the company's compensation strategy for its executives and is indicative of the company's commitment to aligning the interests of its leadership with those of its shareholders.
Senti Biosciences, Inc. (SNTI.US) reported that its Chief Medical & Development Officer, Rajangam Kanya, was granted 101,000 shares of common stock on February 1, 2024. The transaction, which was completed on the same day, was a grant with no cost associated with the acquisition. Following this transaction, Kanya directly holds a total of 101,000 shares in the company. The grant is part of the company's compensation strategy for its executives and is indicative of the company's commitment to aligning the interests of its leadership with those of its shareholders.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more